doi: 10.1161/hc4901.101350
(Circulation. 2001;104:2879.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy Volunteers
Randomized Evaluation of Rofecoxib Versus Naproxen on Endothelium-Dependent Vasodilatation
From the Division of Cardiac Surgery, University of Toronto, Toronto, Ontario (S.V.), and the Division of Cardiology, University of Calgary, Calgary, Alberta (S.V., S.R.R., L.S., K.J.M., T.J.A.), Canada.
Correspondence to Subodh Verma, BPharm, MSc, MD, PhD, Division of Cardiac Surgery, Toronto General Hospital, EN 14-215, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada. E-mail subodh.verma{at}sympatico.ca
Background— From a cardiovascular standpoint, the safety of cyclooxygenase-2 (COX-2) blockers has been a topic of increasing concern. This concern stemmed from observations indicating that the COX-2 isoform is the major source of endothelium-derived prostacyclin and, hence, that selective blockade of this enzyme may impair endothelial health. To investigate this matter, we examined the effects of 7 days of treatment with rofecoxib versus naproxen on endothelial function in healthy volunteers.
Methods and Results— Thirty-five healthy volunteers were randomized to receive 7-day treatment with either rofecoxib (25 mg/d, n=18) or naproxen (750 mg/d, n=17). Vascular response measurements were conducted using forearm strain-gauge plethysmography. Changes in forearm blood flow in response to the endothelium-dependent vasodilator acetylcholine (3, 10, and 30 µg/min) and the endothelium-independent vasodilator sodium nitroprusside (1 and 10 µg/min) were assessed before and after treatment. Acetylcholine evoked a dose-dependent increase in forearm blood flow in all groups. Importantly, treatment resulted in no change in acetylcholine-mediated increases in forearm blood flow in either group (naproxen, P=0.27; rofecoxib, P=0.58). Similarly, there was no change in forearm blood flow in response to sodium nitroprusside (naproxen, P=0.55; rofecoxib, P=0.63).
Conclusions— We herein describe, for the first time, the effects of COX-2-selective inhibition on endothelium-dependent vasodilatation in healthy adults. COX-2 blockade, when used at the doses employed therapeutically (which are known to inhibit vascular prostacyclin production) did not result in significant changes in endothelial vasodilator responses in healthy volunteers. The effects of COX-2 inhibitors on vasodilator responses in patients with coronary artery disease remain to be determined.
Key Words: endothelium-derived factors • patients • prostaglandins
This article has been cited by other articles:
 |
|
 |
|
  T. Klein, M. Eltze, T. Grebe, A. Hatzelmann, and M. Komhoff Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition Cardiovasc Res, July 15, 2007; 75(2): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fazel, R. D. Weisel, and S. Verma A novel technique to assess flow-mediated vasodilation J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1478 - 1480. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bogaty, J. M. Brophy, M. Noel, L. Boyer, S. Simard, F. Bertrand, and G. R. Dagenais Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study Circulation, August 24, 2004; 110(8): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Michelsen, M. H. Wong, P. K. Shah, W. Zhang, J. Yano, T. M. Doherty, S. Akira, T. B. Rajavashisth, and M. Arditi Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E PNAS, July 20, 2004; 101(29): 10679 - 10684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dai and R. A. Kloner Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 51 - 59. [Abstract] [PDF]
|
|
|
|
|
|
S. J Armstrong, Y. Xu, and S. T Davidge Effects of chronic PGHS-2 inhibition on PGHS-dependent vasoconstriction in the aged female rat Cardiovasc Res, February 1, 2004; 61(2): 333 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma and P. E. Szmitko Coxibs and the endothelium J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1754 - 1756. [Full Text] [PDF]
|
|
|
|
|
|
S. Verma, M. R. Buchanan, and T. J. Anderson Endothelial Function Testing as a Biomarker of Vascular Disease Circulation, October 28, 2003; 108(17): 2054 - 2059. [Full Text] [PDF]
|
|
|
|
 |
|
 I. K. Moppett, J. A. Davies, and R. P. Mahajan Non-selective and cyclo-oxygenase-2-specific non-steroidal anti-inflammatory drugs impair the hyperaemic response of skin to brief axillary artery occlusion Br. J. Anaesth., September 1, 2003; 91(3): 353 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Widlansky, D. T. Price, N. Gokce, R. T. Eberhardt, S. J. Duffy, M. Holbrook, C. Maxwell, J. Palmisano, J. F. Keaney Jr, J. D. Morrow, et al. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension Hypertension, September 1, 2003; 42(3): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Yki-Jarvinen, R Bergholm, and M Leirisalo-Repo Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis Ann Rheum Dis, July 1, 2003; 62(7): 630 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Makimattila, M.-R. Taskinen, and H. Yki-Jarvinen Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1637 - 1641. [Abstract] [Full Text] [PDF]
|
|